A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Study Summary

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions / Drugs

MNKD-201(Nintenadib DPI)Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment24 participants

Primary Completion—

Lead SponsorMannkind Corporation

Data Retrieved2026-04-11 04:21:40.354443+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.